Model Portfolios | Institutional | News | Contact

CHB

China Biotech Innovation ETF

Overview Prices & Performance Holdings & Characteristics Research Documents

Reasons to Consider CHB

High Growth Potential

The China biotech market was valued at nearly $40bn in 2021. Forecasts suggest it could surpass $100bn by 2026, highlighting the substantial room for growth.¹

Structural Tailwinds

Health care expenditures in China have grown at an annualized rate of 20% since 2003.² We believe biotech companies are well-positioned to benefit from further growth in this sector.

Targeted Exposure

In contrast to other funds that offer global or broader health care sector exposure, CHB specifically targets the biotech industry in China.

¹Research and Markets, Oct 2022
²Council on Foreign Relations, May 2021

Key Information As of 03/21/23

Inception Date	09/22/20
Total Expense Ratio	0.65%
Net Assets	$2.52 million
NAV	$9.33
Fact Sheet

ETF Summary

The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.

ETF Objective

The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.

Trading Details As of 03/21/23

Ticker	CHB
Bloomberg Index Ticker	SOLCHB
CUSIP	37954Y251
ISIN	US37954Y2515
Primary Exchange	Nasdaq
Shares Outstanding	270,000
Number of Holdings	26
30-Day Median Bid-Ask Spread	1.40%

Distributions As of 03/21/23

30-Day SEC Yield	0.34%
Distribution Frequency	Semi-Annually

ETF Prices As of 03/21/23

NAV	$9.33	Daily Change	$0.32	3.55%
Market Price	$9.37	Daily Change	$0.31	3.42%

As of recent (12/31/22) As of recent (12/31/22)	Fund NAV	Market Price	Index
1 Year	-33.21%	-33.91%	-32.74%
Since Inception	-18.05%	-18.65%	-17.50%
1 Year	-19.41%	-19.03%	-18.82%
Since Inception	-16.35%	-16.25%	-15.80%
Year-to-Date	-33.21%	-33.91%	-32.74%
1 Month	-1.03%	-3.38%	-0.97%
3 Months	12.44%	12.28%	12.60%
Since Inception	-36.40%	-37.46%	-35.43%
Year-to-Date	1.77%	3.82%	1.87%
1 Month	-6.97%	-5.87%	-6.97%
3 Months	0.72%	0.31%	0.89%
Since Inception	-35.27%	-35.07%	-34.22%

Performance is shown on a total return basis (i.e., with gross income reinvested, where applicable). Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated.

Net Assets (%)	Ticker	Name	SEDOL	Market Price ($)	Shares Held	Market Value ($)
9.89	2269 HK	WUXI BIOLOGICS CAYMAN INC	BL6B9P1	6.26	39,750	248,990.00
8.02	300142 C2	WALVAX BIOTECHNOLOGY CO-A	BD5CG36	5.48	36,900	202,071.36
7.88	300122 C2	CHONGQING ZHIF-A	BD5CJY8	13.15	15,100	198,522.88
7.59	000661 C2	CHANGCHUN HIGH-A	BD5CDB3	24.67	7,747	191,155.72
7.55	1093 HK	CSPC PHARMACEUTI	6191997	1.04	183,000	190,077.17
5.30	002252 C2	SHANGHAI RAAS -A	BD5CPJ5	0.88	150,900	133,488.42
5.28	002422 C2	SICHUAN KELUN-A	BD5CL08	4.06	32,700	132,854.81
5.20	ZLAB	ZAI LAB LTD-ADR	BD9GVY0	32.50	4,029	130,942.50
5.06	002007 C2	HUALAN BIOLOGI-A	BD5CL19	3.10	41,100	127,520.54
4.33	1548 HK	GENSCRIPT BIOTECH CORP	BD9Q2J2	2.49	43,850	109,086.41
4.06	300601 C2	SHENZHEN KANGT-A	BFY8HT2	4.69	21,793	102,311.73
4.06	002030 C2	DAAN GENE CO LTD-A	BD5CKW3	2.27	45,080	102,282.66
3.81	300676 C2	BGI GENOMICS CO LTD-A	BFY8H58	8.61	11,138	95,907.48
3.63	1530 HK	3SBIO INC	BY9D3L9	1.03	89,000	91,421.07
3.25	603127 C1	JOINN LABORATO-A	BK94819	7.87	10,404	81,925.07
2.25	300841 C2	CHENGDU KANGHU-A	BMXVCN0	13.65	4,150	56,664.75
2.18	000403 C2	PACIFIC SHUANG-A	BMQ8TB5	3.20	17,100	54,769.88
2.04	300482 C2	GUANGZHOU WOND-A	BFY8GZ1	4.54	11,300	51,326.70
1.81	9966 HK	ALPHAMAB ONCOLOGY	BL6WGG4	2.01	22,700	45,535.68
1.29	002038 C2	BEIJING SL -A	BD5CJD7	1.29	25,200	32,468.42
1.27	603392 C1	BEIJING WANTAI-A	BMXTWX4	17.66	1,815	32,058.80
1.02	603387 C1	GETEIN BIOTECH INC-A	BFB4S90	1.97	13,020	25,626.38
0.95	688185 C1	CANSINO BIOLOGICS INC-A	BMD9JD3	17.50	1,366	23,905.77
0.91	688317 C1	SHANGHAI ZJ BI-A	BQ3RXD3	4.53	5,037	22,820.46
0.79	688526 C1	WUHAN KEQIAN B-A	BQ3RXJ9	3.91	5,076	19,826.66
0.54	9939 HK	KINTOR PHARMACEUTICAL LTD	BMDWVN6	1.05	12,800	13,490.77
0.06		CASH		1.00	1,435	1,434.88

Holdings are subject to change. "Cash" denotes U.S. dollars.

ETF Characteristics As of 03/21/23

Return on Equity	12.30%
Weighted Avg. Market Cap	9,777 M
	2022	2023
Price-to-earnings	39.80	27.32
Price-to-book value	3.50	3.21

Source: AltaVista Research, LLC

ETF Risk Stats As of 02/28/23

Versus	Beta
S&P 500	0.34
MSCI EAFE	0.42
MSCI Emg. Mkts	0.84
Standard Deviation	30.40%

Source: AltaVista Research, LLC

ETF Research

Introducing the Global X China Biotech Innovation ETF (CHB)

J.P. Morgan Healthcare Conference: New Catalysts Set to Transform Patient Care

View More Related Research

ETF Documents

Latest Premium / Discount As of 03/21/23

NAV	$9.33
Market Price	$9.37
Premium / (Discount)	$0.04

Current View 2023 Q1 As of 03/21/23

Days at Premium	27
Days at NAV	0
Days at Discount	27
Greatest Premium	1.46%
Greatest Discount	-2.00%

Daily Premium / Discount History As of 03/21/23

Hover over the chart points for details

View Chart Explanation

Download Chart Data (.CSV)

How can the Fund trade at a premium/discount to its NAV?

The primary explanation is that timing discrepancies can arise between the NAV and the trading price of the Fund. Since shares of the Fund trade on the open market, prices are affected by the constant flow of information received by investors, corporations and financial institutions. Depending on how this changing information affects investor sentiment, shares of the Fund may deviate slightly from the value of the Fund's underlying assets. The NAV of the Fund is only calculated once a day (normally at 4:00 p.m. eastern time). As a result, shareholders may pay more than NAV when they buy Fund shares and receive less than NAV when they sell those shares, because shares are purchased and sold at current market prices. However, due to the creation and redemption process that is unique to ETFs, market makers are able to minimize these deviations from NAV by taking advantage of arbitrage opportunities.

What causes these time discrepancies?

Close of Trading Times. Although both the NAV and the daily market price of the Fund are generally calculated based on prices at the closing time of the exchange (generally 4:00 p.m. eastern time), slight differences in this timing may cause discrepancies.

Time of Last Trade. Trading of Global X funds generally takes place during normal trading hours (9:30 a.m. to 4:00 p.m. eastern time). However, it is important to note that the last trade - from which the closing price is determined - may not occur at exactly 4:00 p.m. eastern time. Therefore, changing market sentiment during the time difference may cause the NAV to deviate from the closing price.

International Holdings. The premiums and discounts for funds with significant holdings in international markets may be less accurate due to the different closing times of various international markets. Because the Funds trade during U.S. market hours while the underlying securities may not, the time lapse between the markets can result in differences between the NAV and the trading price.

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.

CHB